Wet Neovascular Exudative Macular Degeneration-Pipeline Review, H1 2016

Wet Neovascular Exudative Macular Degeneration-Pipeline Review, H1 2016


  • Products Id :- GMDHC7702IDB
  • |
  • Pages: 254
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Wet (Neovascular/Exudative) Macular Degeneration-Pipeline Review, H1 2016', provides an overview of the Wet (Neovascular/Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular/Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular/Exudative) Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular/Exudative) Macular Degeneration

The report reviews pipeline therapeutics for Wet (Neovascular/Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Wet (Neovascular/Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects

The report assesses Wet (Neovascular/Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Wet (Neovascular/Exudative) Macular Degeneration

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular/Exudative) Macular Degeneration

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Wet (Neovascular/Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Wet (Neovascular/Exudative) Macular Degeneration Overview 10

Therapeutics Development 11

Pipeline Products for Wet (Neovascular/Exudative) Macular Degeneration-Overview 11

Wet (Neovascular/Exudative) Macular Degeneration-Therapeutics under Development by Companies 12

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Wet (Neovascular/Exudative) Macular Degeneration-Products under Development by Companies 19

Wet (Neovascular/Exudative) Macular Degeneration-Companies Involved in Therapeutics Development 24

Aciont Inc. 24

Allergan Plc 25

Amakem NV 26

Apellis Pharmaceuticals, Inc. 27

Apexigen, Inc. 28

Applied Genetic Technologies Corporation 29

Avalanche Biotechnologies, Inc. 30

Benitec Biopharma Limited 31

BIOCAD 32

Boehringer Ingelheim GmbH 33

Charlesson LLC. 34

Chong Kun Dang Pharmaceutical Corp. 35

Circadian Technologies Limited 36

Clanotech AB 37

Clearside BioMedical, Inc. 38

Coherus BioSciences, Inc. 39

Daiichi Sankyo Company, Limited 40

Delenex Therapeutics AG 41

Eleven Biotherapeutics Inc. 42

Exonate Limited 43

F. Hoffmann-La Roche Ltd. 44

Formycon AG 45

GTx, Inc. 46

iCo Therapeutics Inc. 47

Icon Bioscience, Inc. 48

Kala Pharmaceuticals, Inc. 49

Kodiak Sciences, Inc. 50

Mabion SA 51

Mitotech S.A. 52

Neurotech Pharmaceuticals, Inc. 53

Ocular Therapeutix, Inc. 54

Ohr Pharmaceutical Inc. 55

Ophthotech Corp. 56

Oxford BioMedica Plc 57

PanOptica, Inc. 58

Pfenex Inc. 59

Pfizer Inc. 60

pSivida Corp. 61

Quark Pharmaceuticals, Inc. 62

Regeneron Pharmaceuticals, Inc. 63

RegenxBio Inc. 64

RXi Pharmaceuticals Corporation 65

Santen Pharmaceutical Co., Ltd. 66

Sanwa Kagaku Kenkyusho Co., Ltd. 67

TRACON Pharmaceuticals, Inc. 68

TWi Pharmaceuticals, Inc. 69

Tyrogenex, Inc. 70

Xbrane Biopharma AB 71

Wet (Neovascular/Exudative) Macular Degeneration-Therapeutics Assessment 72

Assessment by Monotherapy Products 72

Assessment by Combination Products 73

Assessment by Target 74

Assessment by Mechanism of Action 77

Assessment by Route of Administration 80

Assessment by Molecule Type 82

Drug Profiles 84

(aflibercept + nesvacumab)-Drug Profile 84

(aflibercept + rinucumab)-Drug Profile 85

abicipar pegol-Drug Profile 86

AC-301-Drug Profile 89

ACX-107-Drug Profile 90

aflibercept-Drug Profile 91

aflibercept biosimilar-Drug Profile 94

AGN-151200-Drug Profile 95

ALG-1001-Drug Profile 96

AMA-0428-Drug Profile 98

APL-2-Drug Profile 99

APX-003-Drug Profile 101

APX-3330-Drug Profile 102

AVA-101-Drug Profile 104

AVA-201-Drug Profile 106

avacincaptad pegol sodium-Drug Profile 107

AXT-108-Drug Profile 109

bertilimumab-Drug Profile 110

Beta-LGND2-Drug Profile 112

bevacizumab biosimilar-Drug Profile 114

BI-144807-Drug Profile 115

brolucizumab-Drug Profile 116

C-16Y-Drug Profile 118

CLT-005-Drug Profile 119

CLT-28643-Drug Profile 120

cyclosporine-Drug Profile 121

DE-120-Drug Profile 122

DLX-1008-Drug Profile 123

DNX-214-Drug Profile 124

Doxarubicin Pegylated-Drug Profile 125

Drug for Age Related Macular Degeneration-Drug Profile 126

Drug for Wet AMD and Dry AMD-Drug Profile 127

DS-7080-Drug Profile 128

ENV-1305-Drug Profile 129

ENV-705-Drug Profile 130

GB-101-Drug Profile 131

GB-102-Drug Profile 132

Gene Therapy for Wet Age-related Macular Degeneration-Drug Profile 133

K-106-Drug Profile 134

KSI-201-Drug Profile 135

LHA-510-Drug Profile 136

LMG-324-Drug Profile 137

Monoclonal Antibody to Inhibit VEGF for Wet Macular Degeneration-Drug Profile 138

nesvacumab-Drug Profile 139

NT-503-Drug Profile 141

NT-506-Drug Profile 142

OCU-200-Drug Profile 143

OLX-301-Drug Profile 144

ONL-1204-Drug Profile 145

OXB-201-Drug Profile 146

PAN-90806-Drug Profile 147

pegpleranib sodium-Drug Profile 149

PF-05206388-Drug Profile 151

PF-655-Drug Profile 152

plastoquinone decyl triphenylphosphonium bromide-Drug Profile 155

Protein to Inhibit VEGF for Wet Age Related Macular Degeneration-Drug Profile 157

ranibizumab-Drug Profile 158

ranibizumab biosimilar-Drug Profile 162

ranibizumab biosimilar-Drug Profile 163

ranibizumab biosimilar-Drug Profile 164

ranibizumab biosimilar-Drug Profile 166

ranibizumab biosimilar-Drug Profile 167

ranibizumab biosimilar-Drug Profile 168

ranibizumab biosimilar-Drug Profile 169

Recombinant Protein for Age Related Macular Degeneration-Drug Profile 170

Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration-Drug Profile 171

RG-7716-Drug Profile 172

RGX-314-Drug Profile 173

RXI-109-Drug Profile 174

SK-1011-Drug Profile 176

Small Molecules for Dry and Wet Age Related Macular Degeneration-Drug Profile 177

Small Molecules to Inhibit VEGF and PDGF for Wet AMD-Drug Profile 178

SPHINX-31-Drug Profile 180

squalamine lactate-Drug Profile 181

Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration-Drug Profile 184

TRC-105-Drug Profile 185

triamcinolone acetonide-Drug Profile 188

TT-211-Drug Profile 189

TT-231-Drug Profile 190

VGX-300-Drug Profile 191

X-82-Drug Profile 193

Wet (Neovascular/Exudative) Macular Degeneration-Recent Pipeline Updates 195

Wet (Neovascular/Exudative) Macular Degeneration-Dormant Projects 235

Wet (Neovascular/Exudative) Macular Degeneration-Dormant Projects 235

Wet (Neovascular/Exudative) Macular Degeneration-Discontinued Products 238

Wet (Neovascular/Exudative) Macular Degeneration-Product Development Milestones 239

Featured News & Press Releases 239

Appendix 247

Methodology 247

Coverage 247

Secondary Research 247

Primary Research 247

Expert Panel Validation 247

Contact Us 247

Disclaimer 248

List of Figures

Number of Products under Development for Wet (Neovascular/Exudative) Macular Degeneration, H1 2016 17

Number of Products under Development by Companies, H1 2016 18

Comparative Analysis by Late Stage Development, H1 2016 22

Comparative Analysis by Clinical Stage Development, H1 2016 23

Comparative Analysis by Early Stage Products, H1 2016 24

Assessment by Monotherapy Products, H1 2016 78

Assessment by Combination Products, H1 2016 79

Number of Products by Top 10 Targets, H1 2016 80

Number of Products by Stage and Top 10 Targets, H1 2016 80

Number of Products by Top 10 Mechanism of Actions, H1 2016 83

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 83

Number of Products by Top 10 Routes of Administration, H1 2016 86

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 86

Number of Products by Top 10 Molecule Types, H1 2016 88

Number of Products by Stage and Top 10 Molecule Types, H1 2016 88

List of Tables

Number of Products under Development for Wet (Neovascular/Exudative) Macular Degeneration, H1 2016 17

Number of Products under Development by Companies, H1 2016 18

Number of Products under Development by Companies, H1 2016 (Contd..1) 19

Number of Products under Development by Companies, H1 2016 (Contd..2) 20

Number of Products under Development by Companies, H1 2016 (Contd..3) 21

Comparative Analysis by Late Stage Development, H1 2016 22

Comparative Analysis by Clinical Stage Development, H1 2016 23

Comparative Analysis by Early Stage Development, H1 2016 24

Products under Development by Companies, H1 2016 25

Products under Development by Companies, H1 2016 (Contd..1) 26

Products under Development by Companies, H1 2016 (Contd..2) 27

Products under Development by Companies, H1 2016 (Contd..3) 28

Products under Development by Companies, H1 2016 (Contd..4) 29

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Aciont Inc., H1 2016 30

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Allergan Plc, H1 2016 31

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Amakem NV, H1 2016 32

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Apellis Pharmaceuticals, Inc., H1 2016 33

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Apexigen, Inc., H1 2016 34

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Applied Genetic Technologies Corporation, H1 2016 35

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Avalanche Biotechnologies, Inc., H1 2016 36

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Benitec Biopharma Limited, H1 2016 37

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by BIOCAD, H1 2016 38

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Boehringer Ingelheim GmbH, H1 2016 39

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Charlesson LLC., H1 2016 40

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 41

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Circadian Technologies Limited, H1 2016 42

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Clanotech AB, H1 2016 43

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Clearside BioMedical, Inc., H1 2016 44

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Coherus BioSciences, Inc., H1 2016 45

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Daiichi Sankyo Company, Limited, H1 2016 46

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Delenex Therapeutics AG, H1 2016 47

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Eleven Biotherapeutics Inc., H1 2016 48

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Exonate Limited, H1 2016 49

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 50

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Formycon AG, H1 2016 51

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by GTx, Inc., H1 2016 52

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by iCo Therapeutics Inc., H1 2016 53

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Icon Bioscience, Inc., H1 2016 54

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Kala Pharmaceuticals, Inc., H1 2016 55

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Kodiak Sciences, Inc., H1 2016 56

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Mabion SA, H1 2016 57

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Mitotech S.A., H1 2016 58

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Neurotech Pharmaceuticals, Inc., H1 2016 59

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Ocular Therapeutix, Inc., H1 2016 60

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Ohr Pharmaceutical Inc., H1 2016 61

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Ophthotech Corp., H1 2016 62

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Oxford BioMedica Plc, H1 2016 63

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by PanOptica, Inc., H1 2016 64

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Pfenex Inc., H1 2016 65

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Pfizer Inc., H1 2016 66

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by pSivida Corp., H1 2016 67

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Quark Pharmaceuticals, Inc., H1 2016 68

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 69

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by RegenxBio Inc., H1 2016 70

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by RXi Pharmaceuticals Corporation, H1 2016 71

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 72

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016 73

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 74

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by TWi Pharmaceuticals, Inc., H1 2016 75

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Tyrogenex, Inc., H1 2016 76

Wet (Neovascular/Exudative) Macular Degeneration-Pipeline by Xbrane Biopharma AB, H1 2016 77

Assessment by Monotherapy Products, H1 2016 78

Assessment by Combination Products, H1 2016 79

Number of Products by Stage and Target, H1 2016 81

Number of Products by Stage and Mechanism of Action, H1 2016 84

Number of Products by Stage and Route of Administration, H1 2016 87

Number of Products by Stage and Molecule Type, H1 2016 89

Wet (Neovascular/Exudative) Macular Degeneration Therapeutics-Recent Pipeline Updates, H1 2016 201

Wet (Neovascular/Exudative) Macular Degeneration-Dormant Projects, H1 2016 241

Wet (Neovascular/Exudative) Macular Degeneration-Dormant Projects (Contd..1), H1 2016 242

Wet (Neovascular/Exudative) Macular Degeneration-Dormant Projects (Contd..2), H1 2016 243

Wet (Neovascular/Exudative) Macular Degeneration-Discontinued Products, H1 2016 244

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aciont Inc.

Allergan Plc

Amakem NV

Apellis Pharmaceuticals, Inc.

Apexigen, Inc.

Applied Genetic Technologies Corporation

Avalanche Biotechnologies, Inc.

Benitec Biopharma Limited

BIOCAD

Boehringer Ingelheim GmbH

Charlesson LLC.

Chong Kun Dang Pharmaceutical Corp.

Circadian Technologies Limited

Clanotech AB

Clearside BioMedical, Inc.

Coherus BioSciences, Inc.

Daiichi Sankyo Company, Limited

Delenex Therapeutics AG

Eleven Biotherapeutics Inc.

Exonate Limited

F. Hoffmann-La Roche Ltd.

Formycon AG

GTx, Inc.

iCo Therapeutics Inc.

Icon Bioscience, Inc.

Kala Pharmaceuticals, Inc.

Kodiak Sciences, Inc.

Mabion SA

Mitotech S.A.

Neurotech Pharmaceuticals, Inc.

Ocular Therapeutix, Inc.

Ohr Pharmaceutical Inc.

Ophthotech Corp.

Oxford BioMedica Plc

PanOptica, Inc.

Pfenex Inc.

Pfizer Inc.

pSivida Corp.

Quark Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

RegenxBio Inc.

RXi Pharmaceuticals Corporation

Santen Pharmaceutical Co., Ltd.

Sanwa Kagaku Kenkyusho Co., Ltd.

TRACON Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc.

Tyrogenex, Inc.

Xbrane Biopharma AB

Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Products under Development, Key Players in Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Wet (Neovascular / Exudative) Macular Degeneration Pipeline Overview, Wet (Neovascular / Exudative) Macular Degeneration Pipeline, Wet (Neovascular / Exudative) Macular Degeneration Pipeline Assessment

select a license

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com